Singh Rohit Kumar, Gideon Manav, Rajendran Rohan, Mathew Georgie, Nair Kannan
Department of Urology, Amrita Institute of Medical Sciences, Kochi, India.
Mch Urology, Amrita Institute of Medical Sciences, Kochi, India.
J Kidney Cancer VHL. 2023 Oct 4;10(4):1-6. doi: 10.15586/jkcvhl.v10i4.303. eCollection 2023.
Our study aims to discern the immediate and intermediate-term oncological outcomes of the patients with small renal mass and who were surgically unfit or were having a bilateral tumor and underwent radiofrequency ablation (RFA) of the mass. We retrospectively and prospectively analyzed the status of the patients who were diagnosed to have small renal masses and were biopsy-proven renal cell carcinoma (RCC) cases, who underwent RFA at our institute from the year 2013 to 2022. Patients were followed-up for 3 years. Data regarding complications were analyzed for all patients who underwent renal RFA along with the 3-year recurrence-free survival (RFS) rate. A total of 28 patients were eligible for the study based on our inclusion and exclusion criteria. Their renal function was recorded. They underwent RFA and were followed-up for a period of 3 years for RFS. Four patients out of the total had immediate complications, out of which two developed a hematoma. Three-year-follow-ups showed six recurrences, overall having 78.6% RFS. Post-procedural renal function was stable as documented by Estimated glomerular filtration rate. Oncological results of RFA in patients with small renal masses who are surgically unfit are associated with a low risk of immediate and intermediate-term deterioration of renal function.
我们的研究旨在明确肾小肿块患者的近期和中期肿瘤学结局，这些患者手术条件不佳或患有双侧肿瘤，并接受了肿块的射频消融（RFA）治疗。我们对2013年至2022年期间在我院被诊断为肾小肿块且经活检证实为肾细胞癌（RCC）并接受RFA治疗的患者情况进行了回顾性和前瞻性分析。对患者进行了3年的随访。分析了所有接受肾脏RFA治疗患者的并发症数据以及3年无复发生存率（RFS）。根据我们的纳入和排除标准，共有28例患者符合研究条件。记录了他们的肾功能。他们接受了RFA治疗，并随访3年以观察RFS情况。总共有4例患者出现近期并发症，其中2例出现血肿。3年随访显示有6例复发，总体RFS为78.6%。根据估计肾小球滤过率记录，术后肾功能稳定。手术条件不佳的肾小肿块患者接受RFA治疗的肿瘤学结局与近期和中期肾功能恶化的低风险相关。
